InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today ann ...

Scientists have discovered that the enzyme TYK2 modifies tau proteins, leading to their accumulation in the brain—a key ...

Baricitinib, an inhibitor of JAK1/2, was approved by both the FDA and European Medicines Agency in 2022 to treat moderate to ...

Alumis Inc. (ALMS) has received a new Buy rating, initiated by Robert W. Baird analyst, Brian Skorney. Brian Skorney has given his Buy rating ...

Innocare Pharma Ltd.’s tyrosine kinase 2 (TYK2) inhibitor, ICP-488, met the primary endpoint in a phase II trial in Chinese patients with moderate to severe plaque psoriasis, and the results clear the ...

The release said the first project is for a brain-penetrant TYK2 inhibitor that “has the potential to significantly advance the treatment of both the relapsing and progressive forms of multiple ...

Alumis’ lead drug candidate, ESK-001, is a Tyrosine Kinase 2 (TYK2) inhibitor currently in Phase 3 trials for moderate-to-severe plaque psoriasis (PsO) and in Phase 2 trials for systemic lupus ...

The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer as a treatment for autoimmune diseases.

Topline results are anticipated in 2026. The Phase 1 clinical study of A-005, a potential first-in-class, central nervous system (CNS) penetrant TYK2 inhibitor being developed for the treatment of ...